GK Wealth Management LLC Cuts Stock Holdings in DexCom, Inc. $DXCM

GK Wealth Management LLC cut its stake in DexCom, Inc. (NASDAQ:DXCM) by 27.7% in the second quarter, Holdings Channel.com reports. The firm owned 3,013 shares of the medical device company’s stock after selling 1,154 shares during the quarter. GK Wealth Management LLC’s holdings in DexCom were worth $263,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in DXCM. Brighton Jones LLC lifted its holdings in DexCom by 257.7% in the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after acquiring an additional 11,946 shares during the last quarter. Bank Pictet & Cie Europe AG lifted its holdings in DexCom by 1.8% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 111,063 shares of the medical device company’s stock valued at $8,637,000 after acquiring an additional 2,010 shares during the last quarter. Focus Partners Wealth acquired a new position in DexCom in the fourth quarter valued at approximately $496,000. Quantinno Capital Management LP lifted its holdings in DexCom by 189.3% in the fourth quarter. Quantinno Capital Management LP now owns 65,289 shares of the medical device company’s stock valued at $5,078,000 after acquiring an additional 42,718 shares during the last quarter. Finally, Snowden Capital Advisors LLC lifted its holdings in DexCom by 23.4% in the fourth quarter. Snowden Capital Advisors LLC now owns 8,170 shares of the medical device company’s stock valued at $635,000 after acquiring an additional 1,548 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $76.22 on Monday. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. The company has a market cap of $29.89 billion, a P/E ratio of 52.93, a PEG ratio of 1.60 and a beta of 1.48. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $93.25. The company has a 50-day moving average price of $80.88 and a 200 day moving average price of $78.58.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter last year, the firm earned $0.43 earnings per share. The firm’s revenue was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. Research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Activity at DexCom

In other news, EVP Michael Jon Brown sold 500 shares of DexCom stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $80.29, for a total transaction of $40,145.00. Following the completion of the sale, the executive vice president directly owned 94,102 shares in the company, valued at approximately $7,555,449.58. This trade represents a 0.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mark G. Foletta sold 2,750 shares of DexCom stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $81.06, for a total transaction of $222,915.00. Following the sale, the director owned 51,121 shares of the company’s stock, valued at approximately $4,143,868.26. The trade was a 5.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 8,315 shares of company stock valued at $689,431 in the last 90 days. Insiders own 0.32% of the company’s stock.

Analyst Ratings Changes

DXCM has been the topic of a number of research reports. Oppenheimer cut DexCom from an “outperform” rating to a “market perform” rating in a research note on Monday, September 8th. Mizuho upped their price target on DexCom from $95.00 to $100.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 16th. Raymond James Financial upped their price target on DexCom from $99.00 to $102.00 and gave the stock a “strong-buy” rating in a research note on Thursday, July 31st. Barclays upped their price target on DexCom from $93.00 to $98.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 30th. Finally, Piper Sandler upped their price objective on DexCom from $90.00 to $100.00 and gave the stock an “overweight” rating in a research report on Thursday, July 31st. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $99.89.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.